Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Elizabeth I. Buchbinder"'
Autor:
F. Stephen Hodi, Lisa Magarace, Jason L. Weirather, Brian J. Quattrochi, Nancy Bailey, Rizwan Haq, Michael Manos, Lynette M. Sholl, Patrick A. Ott, Elizabeth I. Buchbinder, Ryan C. Brennick, Anita Giobbie-Hurder, Peter Bowling, Benjamin Izar
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2627-2635 (2021)
Cancer Medicine
Cancer Medicine
Mucosal melanoma is a rare form of melanoma which arises from melanocytes in the mucosal membranes and can be effectively treated with immune checkpoint blockade (ICB). However, response rates in mucosal melanoma are lower than those observed for cut
Autor:
Donald P. Lawrence, Kathleen L. Pfaff, Kristen Felt, Elizabeth I. Buchbinder, Anita Giobbie-Hurder, Patrick A. Ott, David F. McDermott, Evisa Gjini, Mariano Severgnini, Jacquelyn O. Wolff, Matthew Nazzaro, Ryan J. Sullivan, Rizwan Haq, Scott J. Rodig, F. Stephen Hodi
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
BackgroundAngiogenic factors promote the growth of tumor vasculature, modulate lymphocyte trafficking into tumors, and inhibit maturation of dendritic cells. We hypothesized that MEDI3617, a human IgG1 kappa monoclonal antibody directed against human
Autor:
Elizabeth I. Buchbinder
Publikováno v:
Hematology/oncology clinics of North America. 35(1)
Immunotherapy with immune checkpoint inhibition has dramatically changed the treatment of melanoma. Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 are approved for the treatment
Autor:
Rizwan Haq, Kristina M. Kelley, Meredith Davis, Anita Giobbie-Hurder, Romualdo Barroso-Sousa, Rona S. Carroll, Hilary Donahue, Maria Gargano, Kevin Zhang, Sara M. Tolaney, Hyunju Lee, Le Min, Patrick A. Ott, Ursula B. Kaiser, F. Stephen Hodi, Elizabeth I. Buchbinder
Publikováno v:
Cancer Immunology Research. 5:1133-1140
Thyroid disorders have emerged as one of the most common immune-related adverse events associated with anti–PD-1 monotherapy or combination anti–PD-1 and anti–CTLA-4 therapy. This study characterizes and compares the evolution of monotherapy an
Autor:
David F. McDermott, Sapna Pradyuman Patel, Gerald P Miletello, Brendan D. Curti, Ann W. Silk, Janice P. Dutcher, Rene Gonzalez, Mayer Fishman, Scott S. Tykodi, Elizabeth I. Buchbinder, Joseph I. Clark, Gregory A. Daniels, Shernan G. Holtan, Christopher D. Lao, John M. Richart
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Background Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in
Publikováno v:
American Journal of Clinical Oncology. 39:98-106
The cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) immune checkpoints are negative regulators of T-cell immune function. Inhibition of these targets, resulting in increased activation of the immune system, has led
Autor:
Brian M. Alexander, Patrick A. Ott, Ayal A. Aizer, F. Stephen Hodi, Elizabeth I. Buchbinder, Daniel N. Cagney
Publikováno v:
Journal of neuro-oncology. 133(1)
Novel systemic therapies with anti-tumor activity in the brain including small molecules targeting BRAF and MEK, and immune checkpoint inhibition, offer the possibility of improved control of intracranial disease. A number of prospective trials suppo
Autor:
Luke R.G. Pike, Monica Krishnan, Alexander Spektor, Brian M. Alexander, Andrew Bang, F. Stephen Hodi, Patrick A. Ott, Paul J. Catalano, Allison Taylor, Mark M. Awad, Tracy A. Balboni, Bhupendra Rawal, Ayal A. Aizer, Daniel N. Cagney, Elizabeth I. Buchbinder, Leena Gandhi, Jonathan D. Schoenfeld
Publikováno v:
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 124(1)
Background and purpose Patients with metastatic melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) are increasingly treated with immune checkpoint blockade targeting the programed death (PD)-1 receptor, often with palliative
Autor:
Gregory A. Daniels, John M. Richart, Elizabeth I. Buchbinder, Jessica C. Perritt, John M. Kirkwood, Marc S. Ernstoff, Howard L. Kaufman, David F. McDermott, Michael A. Morse, Sigrun Hallmeyer, Anasuya Gunturi, Girald P. Miletello, Brendan D. Curti, Sandra Aung, Janice P. Dutcher, Ryan J. Sullivan, Rene Gonzalez, Sapna Pradyuman Patel, Joseph I. Clark, Joe Lutzky
Publikováno v:
Journal for Immunotherapy of Cancer
Background High dose interleukin-2 (HD IL-2) can induce durable responses in a subset of patients leading to long-term survival. Immune checkpoint blockade (ICB) has demonstrated similarly durable responses in a larger proportion of patients. However
The relationship between cancer and the immune system is complex and provides unique therapeutic opportunities. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a regulatory molecule that suppresses T cell effector function following initial activation b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74cdb66678a5aed8cc5df3d17b7fb4a6
https://europepmc.org/articles/PMC4588295/
https://europepmc.org/articles/PMC4588295/